Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
58.75-1.19 (-1.99%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close59.94
Open59.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range58.56 - 59.67
52 Week Range49.70 - 86.31
Volume111,657
Avg. Volume158,027
Market Cap43.856B
Beta (5Y Monthly)0.67
PE Ratio (TTM)44.85
EPS (TTM)1.31
Earnings DateN/A
Forward Dividend & Yield0.30 (0.51%)
Ex-Dividend DateMay 09, 2022
1y Target Est89.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LZAGY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • LONZA GROUP AG UNSP ADR EACH RE
    Analyst Report: Coloplast A/SColoplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy-care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and wound-care markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Reuters

    UPDATE 1-Lonza's first-half core EBITDA gains 16.5%

    Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

  • Reuters

    Lonza's first-half core EBITDA gains 16.5%

    (Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

  • PR Newswire

    HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

    HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab.

Advertisement
Advertisement